Form 4: Ionis Pharmaceuticals EVP Sells Shares Under 10b5-1 Trading Plan
SEC Form 4
Patrick R. O'Neil, EVP, CLO & General Counsel of Ionis Pharmaceuticals, sold 1,207 shares of common stock at $32.35 per share on February 20, 2025, under a pre-arranged 10b5-1 trading plan.
Summary
- On February 20, 2025, Patrick R. O'Neil, the EVP, CLO & General Counsel of Ionis Pharmaceuticals, sold 1,207 shares of the company's common stock.
- The sale was executed at a price of $32.35 per share.
- The transaction was conducted under a Rule 10b5-1 trading plan adopted by O'Neil on February 21, 2024.
- Following the transaction, O'Neil beneficially owns 56,245 shares of Ionis Pharmaceuticals' common stock.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the transaction is a routine sale under a pre-arranged trading plan and doesn't necessarily indicate a negative outlook on the company.
Industry Context
Insider sales are a common occurrence, and the use of 10b5-1 plans allows insiders to sell shares without being accused of trading on non-public information. The market typically views sales by executives with caution, but the existence of a 10b5-1 plan mitigates some of the negative sentiment.
Key Dates
| Date | Description |
|---|---|
| 02/21/2024 | Date the reporting person adopted the Rule 10b5-1 Trading Plan |
| 02/20/2025 | Date of the transaction (stock sale) |
| 02/24/2025 | Date of signature on the Form 4 filing |
Keywords
Ionis Pharmaceuticals, Patrick R. O'Neil, Form 4, insider trading, stock sale, Rule 10b5-1, IONS
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.